Search results for "Roth"

showing 10 items of 806 documents

SARS CoV2 infection _The longevity study perspectives

2021

Graphical abstract

MaleAgingssRNA single-stranded RNARFLP restriction fragment length polymorphismHSPs heat shock proteinsReviewPTMs post-translational modificationsSevere Acute Respiratory SyndromeBiochemistryHIV-1 human immunodeficiency virus-1TNF-α tumor necrosis factor-αEC endothelial cells0302 clinical medicineFluAV influenza A virusI insertionMedicineIFN-γ interferon-γDIC disseminated intravascular coagulationPCR Polymerase Chain Reactionmedia_commonAged 80 and overLongevityRBD receptor-binding domainNeurologyLongevity modelMI myocardial infarctionNK natural killerhPIV2 human parainfluenza virus type 2media_common.quotation_subjectResearching genetic basis of resistance and potential pharmacological targetsLongevityDBP diastolic blood pressureNF-Kb nuclear transcription factor kBRANTES regulated upon activation normal T cell expressed and secretedMphi human macrophages03 medical and health sciencesCox 2 cyclooxygenase 2ORF open reading framePT prothrombin timeSettore MED/05 - Patologia ClinicaHumansMolecular BiologyInflammatory genesARDS acute respiratory distress syndromeNO nitric oxideD deletionCpGIs CpG islandsT2DM type 2 diabetes mellitusmedicine.diseaseFDP fibrin degradation products030104 developmental biologySARS CoV2 severe acute respiratory syndrome Coronavirus 2 virusImmunologyBMI body max indexItalian nonagenarians/centenariansRSV respiratory syncytial virusComplication030217 neurology & neurosurgeryMAPK mitogen-activated protein kinaseIP-10 IFN-γ -Inducible Protein 1040301 basic medicineAT1R activity of angiotensin 1 receptorsDCs dentritic cellsSSCP single strand conformation polymorphismACE/DD polymorphism of the angiotensin converting enzymeFGF21 fibroblast growth factor 21TLR4 toll-like receptor 4NAD nicotinamide adenine dinucleotideACE angiotensin-I converting enzymeAT2R activity of angiotensin 2 receptorsCOVID-19 Coronavirus disease 2019Respiratory distressACE2 angiotensin converting enzyme 2MKP-1 mitogen-activated protein kinase phosphatase-1 ()PD protease domainSNP single nucleotide polymorphismEH essential hypertensionTNFR tumor necrosis factor receptorINR international normalized ratio of the prothrombin timePAI-1 plasminogen activator inhibitor-1Ang angiotensinLPS lipopolysaccharideMCP1 monocyte chemoattractant protein-1medicine.symptomaPTT partial thromboplastin timeBiotechnologyDUSP1 dual specificity phosphatase 1Coronavirus disease 2019 (COVID-19)PC prostate cancerRAS renin-angiotensin aldosterone systemCCR5Δ32 genetic variant of chemokine receptorCOVID-19 Researching genetic basis of resistance and potential pharmacological targets Italian nonagenarians/centenarians Longevity modelAsymptomaticSARS-1 severe acute respiratory syndrome virus 1SIRT-1 Sirtuin 1Th1 t-helper lymphocyte type 1Immune systemROS reactive oxygen speciesTGF-β transforming growth factor betaET-1 endothelin-1ComputingMethodologies_COMPUTERGRAPHICSADAM-17 metallopeptidase domain 17business.industrySARS-CoV-2SBP systolic blood pressureCOVID-19HDACs histone deacetylasesComorbidityImmune Systembusiness5-LO lipoxygenase 5Ageing Research Reviews
researchProduct

Vinflunine in Metastatic Urothelial Carcinoma of the Bladder in Progression after a Platinum-Containing Regimen

2019

<b><i>Background:</i></b> Vinflunine is a microtubule inhibitor of the vinca alkaloid class approved for the treatment of urothelial bladder carcinoma after a platinum-containing regimen. <b><i>Methods:</i></b> To evaluate the effectiveness of vinflunine, we enrolled 80 subjects with a histologically confirmed diagnosis of metastatic urothelial bladder carcinoma that had previously undergone chemotherapy with a platinum-containing regimen and had measurable lesions according to the Response Evaluation Criteria in Solid Tumors (RECIST). The patients (<i>n</i> = 80) received vinflunine (Javlor®) every 3 weeks at 320 mg/m<sup>2&…

MaleCancer ResearchJavlor®medicine.medical_treatmentMetastasichemistry.chemical_compound0302 clinical medicineRetrospective StudieAntineoplastic Combined Chemotherapy Protocols030212 general & internal medicineNeoplasm MetastasisAged 80 and overVinflunineGeneral MedicineMiddle AgedTolerabilityNeoplasm MetastasiOncologyTolerabilityResponse Evaluation Criteria in Solid Tumors030220 oncology & carcinogenesisUrinary Bladder NeoplasmUrothelial carcinomaFemaleHumanmedicine.medical_specialtyMetastatic Urothelial Carcinomamedicine.drug_classBladderUrologyPainVinblastineVinca alkaloid03 medical and health sciencesCarcinomamedicineHumansChemotherapyRetrospective StudiesAgedChemotherapyAntineoplastic Combined Chemotherapy ProtocolToxicitybusiness.industrymedicine.diseaseRegimenUrinary Bladder NeoplasmschemistryCisplatinbusiness
researchProduct

Measurement of Duloxetine in Blood Using High-performance Liquid Chromatography with Spectrophotometric Detection and Column Switching

2007

A method using high-performance liquid chromatography (HPLC) with column switching and ultraviolet (UV) spectroscopy was developed for the determination of duloxetine in human plasma. After centrifugation and addition of venlafaxine as internal standard, plasma samples were injected into the HPLC system and precleaned on a column (10 x 4.0 mm) filled with cyanopropyl (CN)-modified silica of 20 microm particle size, with use of 8% (vol/vol) acetonitrile in deionized water as eluent. Duloxetine was eluted and separated on a LiChrospher 100 CN (5-microm particle size; column size, 250 x 4.6 mm I.D.) using acetonitrile-water-potassium dihydrogenphosphate trihydrate buffer (pH, 6.4; 50:50 vol/vo…

MaleChlorprothixeneThiophenesDuloxetine HydrochlorideDuloxetine HydrochlorideHigh-performance liquid chromatographyColumn chromatographyPharmacokineticsmedicineHumansDrug InteractionsPharmacology (medical)Chromatography High Pressure LiquidPharmacologyDetection limitChromatographyMolecular Structuremedicine.diagnostic_testElutionChemistrySpectrophotometryTherapeutic drug monitoringFemaleDrug MonitoringSelective Serotonin Reuptake Inhibitorsmedicine.drugTherapeutic Drug Monitoring
researchProduct

Studies on the Intravesical Action of Topically Administered G 3 H-Doxorubicin Hydrochloride in Men: Plasma Uptake and Tumor Penetration

1980

AbstractDoxorubicin hydrochloride has been used for the treatment and prevention of recurrences of transitional cell carcinoma. Ideal indications for the drug and side effects have not been determined. In this regard the penetration of the drug into the bladder wall and the urothelium as a urinary blood barrier is of interest. Using a tritium label we have investigated tumor penetration and transmucosal plasma uptake of doxorubicin hydrochloride after intravesical application in 7 patients with stage A bladder tumors. Of the 7 patients 5 were free of tumor following transurethral resection and 2 had recurrent disease. The patients free of tumor received 40mg. doxorubicin hydrochloride per 3…

MaleDrugmedicine.medical_specialtyPathologyHydrochlorideAdministration TopicalUrologymedia_common.quotation_subjectUrinary systemmedicine.medical_treatmentUrinary BladderUrologychemistry.chemical_compoundHumansMedicineUrotheliumSalinemedia_commonCarcinoma Transitional Cellbusiness.industryPapillary tumorMiddle Agedmedicine.diseaseTransitional cell carcinomaUrinary Bladder NeoplasmschemistryDoxorubicinDoxorubicin HydrochlorideNeoplasm Recurrence LocalbusinessJournal of Urology
researchProduct

Mortality and health-related habits in 900 Finnish former elite athletes and their brothers.

2018

BackgroundThere is conflicting evidence on the associations between participation in vigorous sports, health habits, familial factors and subsequent mortality. We investigated all-cause mortality and health-related behaviour among former elite athletes and their brothers.MethodsThe mortality of Finnish male former elite athletes, who had represented Finland between 1920 and 1965 (n=900) and their age-matched brothers (n=900), was followed from the time when athlete started an elite athlete career until 31 December 2015. The age-adjusted HRs were calculated by a paired Cox proportional hazards model. In 2001, surviving participants (n=199 athletes and n=199 age-matched brothers) reported the…

MaleHealth BehaviorPoison controlADULTHOODmortality rate030204 cardiovascular system & hematologySuicide preventionOccupational safety and healthveljetCohort Studies0302 clinical medicinebrothersSurveys and QuestionnairesSELF-RATED HEALTHMedicineOrthopedics and Sports MedicinekohorttitutkimusFinlandSelf-rated healthALL-CAUSE MORTALITYAged 80 and overbiologySmokingTWIN COHORTGeneral Medicine3142 Public health care science environmental and occupational healthCohortCARDIORESPIRATORY FITNESSCohort studyhuippu-urheilijatkuolleisuusAdultmedicine.medical_specialtyelintavatAlcohol DrinkingDISEASE-SPECIFIC MORTALITYPhysical Therapy Sports Therapy and Rehabilitation03 medical and health sciencesYoung AdultInjury preventioncohort studyHumansMortalityCARDIOVASCULAR EVENTSExerciselifestyle habitsAgedProportional Hazards Modelstop athletesbusiness.industryAthletesSiblings030229 sport sciencesbiology.organism_classificationPHYSICAL-ACTIVITYAthletesPhysical therapyRISK-FACTORSbusinessFOLLOW-UPDemographyBritish journal of sports medicine
researchProduct

Hydrops, fetal pleural effusions and chylothorax in three patients with CBL mutations.

2014

Fetal hydrops, fetal pleural effusions, hydrothorax, and chylothorax, may be associated with various genetic disorders, in particular with the Noonan, cardio-facio-cutaneous and Costello syndromes. These syndromes, collectively called RASopathies, are caused by mutations in the RAS/MAPK pathway, which is known to play a major role in lymphangiogenesis. Recently, germline mutations in the Casitas B-cell lymphoma (CBL) gene were reported in 25 patients and of these, 20 had juvenile myelomonocytic leukemia (JMML). The disorder was named "CBL syndrome" or "Noonan syndrome-like disorder with or without juvenile myelomonocytic leukemia" (NSLL). To date, prenatal abnormalities have not been report…

MaleHeterozygoteHydrops FetalisDNA Mutational AnalysisRASopathyChylothoraxGermline mutationhemic and lymphatic diseasesHydrops fetalisGeneticsmedicineHumansProto-Oncogene Proteins c-cblGenetics (clinical)FetusJuvenile myelomonocytic leukemiabusiness.industryChylothoraxFaciesInfantmedicine.diseaseLymphomaPleural EffusionPhenotypeChild PreschoolImmunologyMutationHydrothoraxFemaleRNA Splice SitesbusinessAmerican journal of medical genetics. Part A
researchProduct

Prothrombotic gene variants as risk factors of acute myocardial infarction in young women

2012

Abstract Background Acute myocardial infarction (AMI) in young women represent an extreme phenotype associated with a higher mortality compared with similarly aged men. Prothrombotic gene variants could play a role as risk factors for AMI at young age. Methods We studied Factor V Leiden, FII G20210A, MTHFR C677T and beta-fibrinogen -455G>A variants by real-time PCR in 955 young AMI (362 females) and in 698 AMI (245 females) patients. The data were compared to those obtained in 909 unrelated subjects (458 females) from the general population of the same geographical area (southern Italy). Results In young AMI females, the allelic frequency of either FV Leiden and of FII G20210A was signif…

MaleHomocysteineMyocardial Infarctionlcsh:Medicinegene variantsprothrombotic gene variantsAMIchemistry.chemical_compoundGene FrequencyRisk FactorsgenderMyocardial infarctionMedicine(all)GeneticsYoung AMI Gender AMI Gene variants Mutations Prothrombotic variants Genetic predispositioneducation.field_of_studyprothrombotic variantsbiologyHomozygoteFactor VGeneral MedicineFemaleProthrombinyoung AMIAdultmedicine.medical_specialtyPopulationyoung AMI gender AMI gene variants mutations prothrombotic variants genetic predisposition.Polymorphism Single NucleotideGeneral Biochemistry Genetics and Molecular BiologyInternal medicinemedicineFactor V LeidenGenetic predispositionHumansGenetic Predisposition to Diseasecardiovascular diseaseseducationAllele frequencyAgedBiochemistry Genetics and Molecular Biology(all)business.industryResearchlcsh:RFactor VThrombosismutationsmedicine.diseasechemistryMethylenetetrahydrofolate reductasebiology.proteinbusinessgenetic predispositionJournal of Translational Medicine
researchProduct

Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival.

2016

Venous thromboembolism (VTE) is common in cancer patients. However, little is known about VTE risk in metastatic urothelial carcinoma or variant histologies (UC/VH). We sought to characterize the incidence, associative factors, including whether various chemotherapy regimens portend different risk, and impact of VTE on survival in metastatic UC/VH patients. Patients diagnosed with metastatic UC/VH from 2000 to 2013 were included in this multicenter retrospective, international study from 29 academic institutions. Cumulative and 6-month VTE incidence rates were determined. The association of first-line chemotherapy (divided into six groups) and other baseline characteristics on VTE were anal…

MaleOncologyCancer Researchmedicine.medical_treatmentDisease030204 cardiovascular system & hematologyDeoxycytidine0302 clinical medicineNeoplasm MetastasisOriginal ResearchIncidenceIncidence (epidemiology)Middle AgedPrognosis3. Good healthOncology030220 oncology & carcinogenesischemotherapy survivalbladder cancerFemaleBufeta -- Càncermedicine.drugAdultmedicine.medical_specialtyMetastatic Urothelial Carcinomavenous thromboembolismAntineoplastic Agents[SDV.CAN]Life Sciences [q-bio]/Cancer03 medical and health sciencesInternal medicineUrothelialmedicineHumansRadiology Nuclear Medicine and imagingcardiovascular diseasesAgedRetrospective StudiesTrombosi -- TractamentGynecologyCisplatinCarcinoma Transitional CellChemotherapyBladder cancerbusiness.industryClinical Cancer ResearchCancermedicine.diseaseequipment and suppliesSurvival AnalysisGemcitabineGemcitabineUrinary Bladder NeoplasmsUrothelial;Cisplatinbusiness
researchProduct

Activated prothrombin complex concentrate (FEIBA® ) in acquired haemophilia A: a large multicentre Italian study - the FAIR Registry

2019

MalePediatricsmedicine.medical_specialtyhaemophiliacoagulation factors030204 cardiovascular system & hematologyHemophilia AHaemophilia03 medical and health sciences0302 clinical medicineAcquired haemophiliaHumansMedicinecoagulation factorProspective StudiesRegistriesProspective cohort studyActivated prothrombin complex concentrateRetrospective Studiesbleeding disorders; coagulation factors; factor VIII; haemophilia; Blood Coagulation Factors; Female; Hemophilia A; Humans; Italy; Male; Prospective Studies; Retrospective Studies; Registriesbleeding disordersbleeding disorderbusiness.industryRetrospective cohort studyHematologymedicine.diseaseBlood Coagulation FactorsItalyfactor VIIIFemalebusiness030215 immunologyBritish Journal of Haematology
researchProduct

Interaction of phenylbutazone with racemic phenprocoumon and its enantiomers in rats.

1979

The interaction of phenylbutazone with the enantiomers and racemic [ 3 H]phenprocoumon was studied in male inbred Wistar-Lewis rats following a single i.v. dose of the three forms of phenprocoumon and chronic oral treatment with phenylbutazone (average plasma concentration of about 60 Μg/ml). Phenylbutazone augmented the anticoagulant effect of R(+), S(−), and R, S (±) phenprocoumon to a similar extent. The free fraction of drug in the plasma of the enantiomers and racemic phenprocoumon increased in the presence of phenylbutazone. However, the rate of elimination of total drug from plasma and liver and the distribution between liver and plasma of all three forms of phenprocoumon remained ne…

MalePharmacologyPhenprocoumonElimination rate constantPhenylbutazonemedicineDistribution (pharmacology)AnimalsPharmacology (medical)Drug InteractionsGeneral Pharmacology Toxicology and PharmaceuticsVolume of distributionChemistryAnticoagulantsStereoisomerism4-HydroxycoumarinsDrug interactionRatsKineticsLiverPhenylbutazoneFree fractionPhenprocoumonProthrombinEnantiomermedicine.drugJournal of pharmacokinetics and biopharmaceutics
researchProduct